Latest news for Sumitomo Pharma (OTC:SMDPY) Stock

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Biotech

News

Penny Stocks

Health Care

Contracts

General

DNPUF

NBRV

SMDPY

Nabriva Therapeutics Stock Gains On Positive Lefamulin Data In CABP Patients In China

SUMITO DAIN PHAR UNSP/ADR by SUMITOMO DAINIPPON PHARMA CO LTD

Sumitomo Pharma Co Ltd

WIIM

CARR

Carrier Global shares are trading higher. Multiple analysts maintained an Outperform rating on the stock. The company on Thursday reported mixed Q2 earnings.

CRWD

CrowdStrike Outage Likely To Impact Insurers' Earnings; AM Best Warns Of Potential Insurance Claims And Legal Processes

CREV

Carbon Revolution shares are trading higher after the company reported it has partnered with GM to provide carbon fiber wheels for the Chevrolet Corvette ZR1.

ONMD

OneMedNet shares are trading higher after the company announced a $4.6M private placement.

Aon shares are trading higher after the company reported better-than-expected Q2 revenue results.

RBC Capital analyst Keith Mackey maintains Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) with a Outperform and lowers the price target from $15 to $14.

Price Target

Analyst Ratings

PTEN

RBC Capital Maintains Outperform on Patterson-UTI Energy, Lowers Price Target to $14

COLB

Columbia Banking System shares are trading higher after the company reported better-than-expected Q2 earnings results. Also, multiple firms raised their respective price targets on its stock.

Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) will release its financial results for the first quarter of fiscal year 2025 ended June 30, 2024, before financial markets open&nbsp;on August 9, 2024.
An audio webcast with David Klein, CEO and Judy Hong, CFO  will take place on August 9, at 10 am ET.
<h2 class="wp-block-heading">Canopy&#8217;s European Expansion</h2>
Canopy has been ramping up its presence in the Czech Republic as the country's officials are considering a fully legal commercial adult-use <a href="https://www.benzinga.com/markets/cannabis/24/07/39773667/leaked-documents-czech-republic-plans-to-set-up-legal-recreational-cannabis-market">cannabis market as part of its ‘Cannabis Management Act.&#8217;</a> Its medical brand is servicing other European markets like <a href="https://www.benzinga.com/markets/cannabis/24/07/39773667/leaked-documents-czech-republic-plans-to-set-up-legal-recreational-cannabis-market">Poland</a> and Germany as well, as well as Asia-Pacific markets, including <a href="https://www.benzinga.com/markets/cannabis/23/10/35162207/canopy-growth-shares-up-slightly-in-pre-market-trading-on-eu-gmp-certification-news">Australia and New Zealand.</a> That said, Canopy's International markets cannabis net revenue increased 32% year-over-year to CA$12 million in the <a href="https://www.benzinga.com/markets/cannabis/24/05/39085695/canopy-growth-reports-7-yoy-increase-in-q4-net-revenue-continues-focus-on-innovation-in-canada-a">fourth quarter driven by growth in Germany and Poland.</a>
On the heels of reporting its fourth quarter results for the fiscal year that ended March 31, 2024, Canopy CEO David Klein said the company will seize positive cannabis regulatory shifts in Germany and the United States, Klein added. &#8220;Entering FY2025, Canopy has growing businesses in the world's most attractive cannabis markets, a leading portfolio of high-impact brands, and a rapidly developing U.S. ecosystem."
In early June, Canopy said it has established an at-the-market equity program under which it can issue and sell up to $250 million worth of its common shares from treasury from time to time in concurrent <a href="https://www.benzinga.com/markets/cannabis/24/06/39207292/canopy-growth-announces-250m-at-the-market-equity-program">public offerings in the United States and Canada.</a> The announcement has generated significant buzz within the cannabis industry, as highlighted by Benzinga's <a href="https://www.benzinga.com/author/javier-hasse">Javier Hasse</a> at the time.
"We're pleased to announce this offering, which further enhances Canopy's financial flexibility and balance sheet," Judy Hong,&nbsp;Canopy Growth&#8217;s CFO told Benzinga Cannabis <a href="https://www.benzinga.com/markets/cannabis/24/06/39233003/exclusive-canopy-growth-cfo-on-atm-equity-offering-we-have-one-of-the-strongest-balance-sheets-i">exclusively</a>. "Having already reduced our debt by more than $1.1 billion over the past 18 months, and with no material debt maturing until 2026, Canopy has one of the strongest balance sheets among major cannabis companies."
According to <a href="https://www.benzinga.com/topic/viridian-capital-advisors">Viridian Valuation Tracker</a>'s report in June on Canadian cultivation and retail companies with market caps over $100 million market Canopy is the best performer in the group based on its year-to-date stock performance.
Why? Canopy&#8217;s better performance is <a href="https://dealtracker.viridianca.com/valuation-tracker-by-industry-sector/">attributed</a> to its acquisition of U.S. plant-touching <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39237411/how-these-2-nasdaq-listed-marijuana-companies-found-a-way-to-raise-250m-without-tan">companies into Canopy USA</a>.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39166300/canopy-growth-doubles-down-on-its-usa-strategy-announces-exercise-of-acreage-options">Canopy Growth Doubles Down On Its USA Strategy, Announces Exercise of Acreage Options</a>
CGC shares traded 2.65% higher $7.35 per share at the time of writing on Friday morning.
<h3 class="wp-block-heading">Earnings Calendar For Upcoming Releases</h3>
Weedmaps
<ul>
<li>WM Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) &#8211; also known as Weedmaps &#8211; a leading marketplace and technology solutions provider to the cannabis industry, today announced it will report financial results for its second quarter ended June 30, 2024, after market close on Thursday, August 8, 2024. </li>
<li>Last week, the company reported sales declined by 4.5% year-over-year and quarter-over-quarter in&nbsp;the first quarter of fiscal 2024.&nbsp;According to senior analyst Pablo Zuanic fromZuanic &amp; Associates,&nbsp;MAPS management did not provide FY 2024 guidance but expects stable sales for the second quarter while anticipating EBITDA of around $7 million, down from $9 to $11 million due to increased marketing spend. </li>
<li>Additionally, the recent legalization of <a href="https://www.benzinga.com/topic/ohio-cannabis">recreational cannabis in Ohio</a> is expected to drive growth in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39850838/is-a-1500-increase-possible-the-bull-case-for-this-cannabis-tech-stock-explained">the second half of 2024</a>. On Thursday, the online cannabis marketplace, announced a partnership with NuggMD, to streamline the medical cannabis education and application process for <a href="https://www.benzinga.com/markets/cannabis/24/07/39959663/weedmaps-and-nuggmd-partner-to-launch-medical-cannabis-education-and-application-program">patients through a new pilot program.</a></li>
</ul>
Charlotte&#8217;s Web
<ul>
<li>Charlotte&#8217;s Web Holdings, Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#TSX">CWEB</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTCQX">CWBHF</a>) will report its 2024 second-quarter results prior to the market opening on August 8, 2024. A conference call to review the results is scheduled for the same day at 11:00 am Eastern Time.&nbsp;</li>
<li>The Colorado-based hemp extract wellness producer faced a challenging first quarter, <a href="https://www.benzinga.com/markets/cannabis/24/05/38705530/cbd-focused-charlottes-web-revenue-drops-29-in-q1-amid-strategic-adjustments">reporting a 29% decline in revenue to $12.1 million from $17 million in the same period of fiscal 2023.</a>&nbsp;&nbsp;&nbsp;&nbsp;</li>
</ul>
Cronos Group
<ul>
<li>Cronos Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CRON#TSX">CRON</a>) will hold its 2024 second-quarter earnings conference call on Thursday, August 8, 2024, at 8:30 am Eastern Time. </li>
<li>The company&#8217;s net revenue surged 30% year-over-year, <a href="https://www.benzinga.com/markets/cannabis/24/05/38739086/cronos-cannabis-company-slashes-losses-reports-highest-quarterly-net-revenue-in-q1-2024">reaching</a> $25.3 million in the first quarter reported in May and driven primarily by <a href="https://www.benzinga.com/topic/canada-cannabis">sales in Canada and Israel.</a> </li>
<li>Subsequent to the quarter end, the company announced the expansion of Cronos Growing Company, a cannabis cultivation business of which the Toronto-based company owns 50%. The investment will be funded by a roughly $51 million (CA$70 million) secured non-revolving credit facility provided by Cronos. It will assist GrowCo&#8217;s expansion of its purpose-built cannabis facility in Leamington, Ontario, that will produce high-quality cannabis flower, the <a href="https://www.benzinga.com/markets/cannabis/24/06/39418098/cronos-cannabis-co-will-provide-51m-to-growco-toward-facility-expansion-fund">company said at the time</a>.</li>
</ul>
TILT Holdings
<ul>
<li>TILT Holdings Inc. (Cboe: TILT) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/TLLTF#OTCQB">TLLTF</a>) will host a second-quarter earnings conference call on Friday, August 9, 2024, at 8:30 am Eastern Time. </li>
<li>The company said earlier first-quarter 2024 results revealed disruptions in the vape hardware segment, which accounted for 71% of the company&#8217;s sales in 2023. Despite these challenges, the custom <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38995545/tilt-holdings-cannabis-sales-steady-despite-supply-disruptions-are-debt-and-stock-d">business remained robust,</a> with the company seeing growth opportunities in hemp-derived vapes, remaining the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35228569/whos-who-among-cannabis-hardware-vaping-suppliers-zuanic-associates-take-a-deep-div">largest CCELL distributor in the U.S.</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39797090/when-is-cannabis-giant-tilray-reporting-earnings-and-what-should-investors-expect">When Is Cannabis Giant Tilray Reporting Earnings And What Should Investors Expect?</a></li>
</ul>
Learn more about leading cannabis companies and stocks at&nbsp;the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.

Cannabis

Earnings

CRON

CWBHF

CWEB

MAPS

TILT

TLLTF

TSX:CRON

TSX:CWEB

TSX:WEED

WEED

Canopy Growth And Other Hot Cannabis Stocks Will Soon Report Earnings, What Investors Need To Know Now

MetLife's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) short percent of float has fallen 9.66% since its last report. The company recently reported that it has 7.74 million shares sold short, which is 1.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MetLife Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722003322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MetLife has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MetLife's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MetLife's peer group average for short interest as a percentage of float is 2.97%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About MetLife?

Baker Hughes's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NYSE">BKR</a>) short percent of float has fallen 12.86% since its last report. The company recently reported that it has 18.88 million shares sold short, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.95 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Baker Hughes Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722003317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Baker Hughes has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Baker Hughes's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Baker Hughes's peer group average for short interest as a percentage of float is 7.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Baker Hughes's Recent Short Interest

Archer Aviation's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) short percent of float has risen 15.04% since its last report. The company recently reported that it has 57.86 million shares sold short, which is 26.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Archer Aviation Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722003312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Archer Aviation has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Archer Aviation's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Archer Aviation's peer group average for short interest as a percentage of float is 7.65%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ACHR

Looking Into Archer Aviation's Recent Short Interest

A Georgia homeowner is reeling after what they claim is a real estate agent's blunder that left their house flooded and their wallet hurting.
In a post on Reddit, user Ok_Kaleidoscope wrote that they came home to find their place looking like a water park after an agent showed the house.
The agent cranked the AC to 62 degrees on a Georgia summer day. The extreme cold caused so much condensation that it filled the pans with water and spilled out, soaking carpets, ruining floors, leaking through the ceiling, and leaving a repair bill that could buy a small car.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>
The homeowner says they've got proof the agent was the last one in the house, but the agent is playing dumb. Now, Ok_Kaleidoscope is stuck with a messed-up house and a huge headache.
"It's going to be at least $20K in repairs, and I'm now stuck with a house I can't sell until the repairs are made," Ok_Kaleidoscope wrote.
The post sparked a conversation about who was at fault, and many of those who responded said that filing a lawsuit would be futile because the pan overflowing was the result of a malfunction of a switch that would cause the unit to shutdown until the pan drains through a pipe that channels the water out of the house.
See Also: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
&nbsp;"That pipe was clogged," wrote Intelligent-Bat1724. "Realtor's attorney will claim their client cannot be held responsible for malfunctions of poorly maintained equipment."
Intelligent-Bat1724 also noted that although the homeowner said the air conditioning was turned off, every homeowner's insurance policy includes a provision that they must maintain normal climate control at all times.
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
"By turning off the system, the homeowner breached that provision," wrote Intelligent-Bat1724, a mitigation department manager in the restoration industry. "Some <a href="https://www.benzinga.com/real-estate/24/07/39592564/percentage-of-americans-without-homeowners-insurance-more-than-doubles-in-five-years">insurance carriers </a>may deny a claim for damages sustained as a result of this.
Although some Reddit users suggested filing a claim through their homeowner&#8217;s insurance, others warned that it could result in the company <a href="https://www.benzinga.com/real-estate/24/03/37964319/another-home-insurer-leaves-california-and-eight-other-states">dropping their coverage</a>.
"For every story like yours, I have two dozen who got canceled the next time their policy was up for renewal following a claim," Jenikovista responded to a poster whose guesthouse caught fire and was repaired through an insurance claim.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>

Real Estate

Real Estate Agent's Sunday Showing Turns Into Monday Morning Nightmare

Wells Fargo analyst Marc Torrente maintains Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Overweight and lowers the price target from $98 to $70.

Wells Fargo Maintains Overweight on Lamb Weston Hldgs, Lowers Price Target to $70

Goldman Sachs analyst David Roman maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and lowers the price target from $107 to $91.

Goldman Sachs Maintains Buy on Edwards Lifesciences, Lowers Price Target to $91

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has been in the spotlight recently, and not just because of its futuristic cars or CEO <a href="https://www.benzinga.com/topic/elon-musk">Elon Musk&#8216;s tweets</a>. 
Despite <a href="https://www.benzinga.com/news/earnings/24/07/39918390/tesla-q2-earnings-highlights-revenue-beat-eps-miss-robotaxi-update-2024-growth-rate-to-be-notably-l">a year of ups and downs</a>, the stock is gearing up to form a Golden Cross — a bullish technical indicator that has traders buzzing about a potential turnaround. 
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="633" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26081140/Screenshot-2024-07-26-at-4.50.37-PM.png" alt="" class="wp-image-459234" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26081140/Screenshot-2024-07-26-at-4.50.37-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26081140/Screenshot-2024-07-26-at-4.50.37-PM-300x216.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h3 class="wp-block-heading">Tesla Stock Has Been Treading Rocky Roads</h3>
Let&#8217;s face it: Tesla&#8217;s been on a bit of a rollercoaster. The stock has dropped 16.97% over the past year and is down 11.36% year-to-date. 
Following its second-quarter 2024 earnings report released on July 23, Tesla&#8217;s shares plunged 10.61% as the company missed earnings expectations with an adjusted EPS of 52 cents, falling short of the 62 cents estimate.
However, Tesla did post sales of $25.5 billion, beating the $24.726 billion consensus and showing a modest 2.3% increase from the same period last year.
Despite the mixed financial results and a forecast of lower vehicle volume growth for 2024 compared to 2023, Tesla&#8217;s stock may be on the brink of something promising.
Read Also: <a href="https://www.benzinga.com//node/39918390">Tesla Q2 Earnings Highlights: Revenue Beat, EPS Miss, Robotaxi Update, 2024 Growth Rate To Be &#8216;Notably Lower&#8217; Than 2023</a>
<h3 class="wp-block-heading">The Golden Cross: Tesla's Silver Lining</h3>
Here&#8217;s where it gets interesting: Tesla is about to form a Golden Cross, where its 50-day simple moving average (SMA) of $204.08 is poised to cross above the 200-day SMA of $204.86.
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="633" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26084418/Screenshot-2024-07-26-at-4.51.16-PM.png" alt="" class="wp-image-459364" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26084418/Screenshot-2024-07-26-at-4.51.16-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26084418/Screenshot-2024-07-26-at-4.51.16-PM-300x216.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
For the uninitiated, this crossover is a classic sign of a bullish shift, signaling that momentum is finally swinging in Tesla&#8217;s favor. As of now, Tesla's stock price stands at $224.06, comfortably above both key averages, further fueling the bullish sentiment.
<figure class="wp-block-image size-full"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="633" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26084432/Screenshot-2024-07-26-at-4.49.05-PM.png" alt="" class="wp-image-459365" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26084432/Screenshot-2024-07-26-at-4.49.05-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26084432/Screenshot-2024-07-26-at-4.49.05-PM-300x216.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
But wait, there's more! The Moving Average Convergence Divergence (MACD) indicator is at 7.34, supporting a bullish outlook, while the Relative Strength Index (RSI) sits at 46.95 and treading downwards, indicating the stock is approaching oversold territory. 
Even the Bollinger Bands point to potential gains, stretching from $178.07 to $282.08.
<h3 class="wp-block-heading">What&#8217;s Next For Tesla?</h3>
As Tesla edges closer to this technical milestone, traders and investors alike should keep their eyes peeled. The formation of the Golden Cross could mark a pivotal moment for the car company. 
While the short-term outlook might seem cloudy, Tesla&#8217;s long-term potential is anything but bleak. As the stock gears up for this significant technical move, the electric future of Tesla may just be a little brighter.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39981592/tesla-introduces-new-120-detailing-kit-for-all-of-its-lineup-but-cybertruck">Tesla Introduces New $120 Detailing Kit For All Of Its Lineup But Cybertruck</a></li>
</ul>

Technicals

Tech

TSLA

Tesla Stock Approaches Golden Cross: Is EV Stock Ready To Accelerate?

KNSL

Kinsale Capital Group shares are trading higher after the company reported better-than-expected Q2 financial results.

Wells Fargo analyst Michael Kaye maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Overweight and raises the price target from $24 to $27.

Wells Fargo Maintains Overweight on SLM, Raises Price Target to $27

RBC Capital analyst Rishi Jaluria maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Outperform and raises the price target from $77 to $90.

PEGA

RBC Capital Maintains Outperform on Pegasystems, Raises Price Target to $90

VALE

Vale CEO Says H1 Results Reinforce Confidence And Commitment To Meet Top End Of 2024 Guidance

Goldman Sachs analyst Eric Sheridan maintains Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Sell and lowers the price target from $10.5 to $9.

COUR

Goldman Sachs Maintains Sell on Coursera, Lowers Price Target to $9

Doubling Down On Gain Therapeutics

Tourlite Capital Q1 2024 Investor Letter

ABUS

BAYRY

BAYZF

ESPR

EXAI

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

GANX

GIFLF

GIFOF

GIKLY

GRFS

LGND

LGNDZ

LGNXZ

LGNYZ

LGNZZ

OABI

OABIW

PRGO

PRPL

REAL

ROIV

RXRX

SRPT

VRTX

ZNTL

Sumitomo Pharma

<ul>
	<li>Nabriva Therapeutics&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/nbrv#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">NBRV</a>) and its collaborating partner in China,&nbsp;Sinovant Sciences,&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/05/g21288046/sinovant-sciences-and-nabriva-therapeutics-announce-positive-topline-results-from-phase-3-trial-of" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">have announced positive topline results</a>&nbsp;from Sinovant&#39;s Phase 3 bridging study evaluating lefamulin in Chinese adults with community-acquired bacterial pneumonia (CABP).</li>
	<li>Lefamulin met the primary endpoint of non-inferiority versus moxifloxacin, a broad-spectrum antibiotic for Investigator Assessment of Clinical Response at Test of Cure (IACR-TOC).</li>
	<li>IACR-TOC is defined as the resolution or improvement of a subject&#39;s clinical signs and symptoms without any additional antibacterial therapy.</li>
	<li>Success rates of 76.8% (n = 63/82) for lefamulin and 71.4% (n = 30/42) for moxifloxacin was observed.</li>
	<li>IACR-TOC in the clinically evaluable population, success rates were 86.0% (n = 49/57) and 86.2% (n = 25/29) in the lefamulin and moxifloxacin arms, respectively.</li>
	<li>lefamulin was observed to be generally safe and well-tolerated, with an overall rate of treatment-emergent adverse events comparable to that of moxifloxacin.</li>
	<li>In addition, Sinovant has entered into an agreement with&nbsp;Sumitomo Pharmaceuticals (Suzhou) Co Ltd, a wholly-owned subsidiary of&nbsp;Sumitomo Dainippon Pharma&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/dnpuf#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">DNPUF</a>), to acquire development and commercialization rights for lefamulin in Greater China.</li>
	<li>Lefamulin (marketed by Nabriva in the U.S. as Xenleta) is a semi-synthetic pleuromutilin antibiotic for systemic administration.</li>
	<li>Price Action:&nbsp;NBRV shares are up 60.1% at $2.37 during the premarket session on the last check Wednesday.</li>
</ul>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Sumitomo Pharma

News

Latest news for Sumitomo Pharma (OTC:SMDPY) Stock

Wednesday, May 26, 2021